Related references
Note: Only part of the references are listed.Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer
Ulrich Luecking et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors
Yunsong Tong et al.
ACS MEDICINAL CHEMISTRY LETTERS (2021)
AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells
Justin Cidado et al.
CLINICAL CANCER RESEARCH (2020)
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies
Bernard Barlaam et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer
Ulrich Luecking et al.
CHEMMEDCHEM (2017)
AZ5576, a novel potent and selective CDK9 inhibitor, induces rapid cell death and achieves efficacy in multiple preclinical hematological models
Justin Cidado et al.
CANCER RESEARCH (2016)
Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy
Yogesh A. Sonawane et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
General methods for the synthesis and late-stage diversification of 2,4-substituted 7-azaindoles
Jeffrey G. Varnes et al.
TETRAHEDRON LETTERS (2016)
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs
Concepcion Sanchez-Martinez et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Julia A. Beaver et al.
CLINICAL CANCER RESEARCH (2015)
Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009-2014)
Veronika Malinkova et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2015)
Volume of Distribution in Drug Design
Dennis A. Smith et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner
Shankar Varadarajan et al.
ONCOTARGET (2015)
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Lawrence M. Gelbert et al.
INVESTIGATIONAL NEW DRUGS (2014)
A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models
Tinggui Yin et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia
M-P Garcia-Cuellar et al.
LEUKEMIA (2014)
MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis
Robert N. Booher et al.
PLOS ONE (2014)
Cyclin-dependent kinases
Marcos Malumbres
GENOME BIOLOGY (2014)
Cyclin-dependent kinase inhibitor therapy for hematologic malignancies
Prithviraj Bose et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Cyclin-dependent kinase inhibitors closer to market launch?
Herve Galons et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2013)
Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity
Alison J. Hole et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Cell cycle kinases as therapeutic targets for cancer
Silvia Lapenna et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Cell cycle, CDKs and cancer: a changing paradigm
Marcos Malumbres et al.
NATURE REVIEWS CANCER (2009)
Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology
Shudong Wang et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
Creation of superior carboxyfluorescein dyes by blocking donor-excited photoinduced electron transfer
Tomoko Mineno et al.
ORGANIC LETTERS (2006)
The general transcription machinery and general cofactors
Mary C. Thomas et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2006)
Share Paper
